260 related articles for article (PubMed ID: 16338252)
1. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
[TBL] [Abstract][Full Text] [Related]
2. Relationship between plasma HDL subclasses distribution and lipoprotein lipase gene HindIII polymorphism in hyperlipidemia.
Long S; Tian Y; Zhang R; Yang L; Xu Y; Jia L; Fu M
Clin Chim Acta; 2006 Apr; 366(1-2):316-21. PubMed ID: 16364275
[TBL] [Abstract][Full Text] [Related]
3. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
Cerda A; Genvigir FD; Arazi SS; Hirata MH; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
Clin Chim Acta; 2010 May; 411(9-10):631-7. PubMed ID: 20064494
[TBL] [Abstract][Full Text] [Related]
4. Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment.
García-Otín AL; Civeira F; Aristegui R; Díaz C; Recalde D; Sol JM; Masramon X; Hernández G; Pocoví M;
Eur J Clin Invest; 2002 Jun; 32(6):421-8. PubMed ID: 12059987
[TBL] [Abstract][Full Text] [Related]
5. Fat intake influences the effect of the hepatic lipase C-514T polymorphism on HDL-cholesterol levels in children.
Riestra P; López-Simón L; Ortega H; Gorgojo L; Martin-Moreno JM; Schoppen S; de Oya M; Garcés C
Exp Biol Med (Maywood); 2009 Jul; 234(7):744-9. PubMed ID: 19429860
[TBL] [Abstract][Full Text] [Related]
6. Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate.
Canudas J; Cenarro A; Civeira F; Garcí-Otín AL; Arístegui R; Díaz C; Masramon X; Sol JM; Hernández G; Pocoví M
Metabolism; 2001 Apr; 50(4):447-50. PubMed ID: 11288040
[TBL] [Abstract][Full Text] [Related]
7. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
8. [The linkage disequilibrium of four loci in hepatic lipase promoter gene of cerebral infarction patients in Shanghai].
Fu Y; Ni PH; Ying YY; Liu JR; Song YJ; Xin XY; Guo ZL; Chen SD
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(31):2203-8. PubMed ID: 18001531
[TBL] [Abstract][Full Text] [Related]
9. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
[TBL] [Abstract][Full Text] [Related]
10. Effects of hepatic lipase gene promoter nucleotide variations on serum HDL cholesterol concentration in the general Japanese population.
Inazu A; Nishimura Y; Terada Y; Mabuchi H
J Hum Genet; 2001; 46(4):172-7. PubMed ID: 11322655
[TBL] [Abstract][Full Text] [Related]
11. Association of the -514C-->T polymorphism in the hepatic lipase gene (LIPC) promoter with elevated fasting insulin concentrations, but not insulin resistance, in non-diabetic Germans.
Machicao F; Staiger H; Fritsche A; Guirguis A; Weisser M; Stumvoll M; Häring HU
Horm Metab Res; 2004 May; 36(5):303-6. PubMed ID: 15156410
[TBL] [Abstract][Full Text] [Related]
12. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
13. C-514T polymorphism in hepatic lipase gene promoter is associated with elevated triglyceride levels and decreasing insulin sensitivity in nondiabetic Japanese subjects.
Yabu Y; Noma K; Nakatani K; Nishioka J; Suematsu M; Katsuki A; Hori Y; Yano Y; Sumida Y; Wada H; Nobori T
Int J Mol Med; 2005 Sep; 16(3):421-5. PubMed ID: 16077949
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects.
Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Chim Acta; 2005 Dec; 362(1-2):182-8. PubMed ID: 16038892
[TBL] [Abstract][Full Text] [Related]
15. CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia.
Takata M; Inazu A; Katsuda S; Miwa K; Kawashiri MA; Nohara A; Higashikata T; Kobayashi J; Mabuchi H; Yamagishi M
Clin Sci (Lond); 2006 Nov; 111(5):325-31. PubMed ID: 16822236
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
[TBL] [Abstract][Full Text] [Related]
17. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Avisar I; Brook JG; Wolfovitz E
Eur J Intern Med; 2008 May; 19(3):203-8. PubMed ID: 18395165
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
20. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
Arca M; Natoli S; Micheletta F; Riggi S; Di Angelantonio E; Montali A; Antonini TM; Antonini R; Diczfalusy U; Iuliano L
Free Radic Biol Med; 2007 Mar; 42(5):698-705. PubMed ID: 17291993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
